ACT-541468 is an investigational drug.
There have been 22 clinical trials for ACT-541468.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 4th 2018.
The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Disease, and Liver Diseases. The leading clinical trial sponsors are Idorsia Pharmaceuticals Ltd., Actelion, and University Hospital, Basel, Switzerland.
There are four US patents protecting this investigational drug and eighty-seven international patents.